Relmada Therapeutics Inc (RLMD NASDAQ) stock market data APIs
$7.1175
-0.14(-2%)
as of May 20, 2026
Try our APIs with
free plan!
Relmada Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Prev. Close
7.1175
Open
6.9794
High
7.1751
Low
6.8393
52 wk Range
0.52-8
Market Cap
737 M
Shares Outstanding
105 M
EPS
-0.22
Beta
0.833
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Relmada Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Relmada Therapeutics Inc data using free add-ons & libraries
Get Relmada Therapeutics Inc Fundamental Data
Relmada Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -13 855 048
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Relmada Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-13
- EPS/Forecast: -0.195
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Relmada Therapeutics Inc News
New
After-Hours Earnings Report for May 12, 2026 : FNV, NXT, OKLO, KRMN, REZI, ATRO, CAPR, AIP, EVLV, KURA, RLMD, GAIN
The following companies are expected to report earnings after hours on 05/12/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Franco-Nevada Corporation (FNV)is repo...
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
12-Month Phase 2 data in High-Risk NMIBC to be presented Friday, May 15, 2026Phase 3 overview to be presented at Trials-in-Progress session on Sunday, May 17, 2026The Phase 3 “RESCUE” registration...
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
For Immediate Release Chicago, IL – April 6, 2026 – Today, Zacks Equity Research discusses Indivior Pharmaceuticals INDV, Catalyst Pharmaceuticals CPRX, Theravance Biopharma TBPH, Relmada Therape...
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
The drug and biotech sector has been in a recovery mode since mid-2025, after going through a difficult period between 2021 and 2023 backed by strong quarterly results, surging mergers and acquisition...
Get Relmada Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
